Health & Hype Podcast: A Deeper Dive into DEA Telemedicine Controlled Substances | Foley & Lardner LLP

In the wake of the U.S. Drug Enforcement Agency’s (DEA) notice of a forthcoming proposed rule with a third extension of flexibilities related to telemedicine prescribing of controlled substances, some industry stakeholders anticipate the rule will extend the current DEA telemedicine prescribing flexibilities for at least another year to avoid the Telehealth Cliff.